Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 12, 2012, Pages 1501-1510

  Willart, M A M ^a,b   Van Nimwegen, M ^c   Grefhorst, A ^c   Hammad, H ^a,b   Moons, L ^c   Hoogsteden, H C ^c   Lambrecht, B N ^a,b,c   KleinJan, A ^c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

dendritic cell; eosinophilic airway inflammation; farnesoid X receptor; gastrointestinal tract; ursodeoxycholic acid

Indexed keywords

CYTOKINE; FARNESOID X RECEPTOR; OVALBUMIN; SODIUM CHLORIDE; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC AIRWAY INFLAMMATION; FEMALE; GASTROINTESTINAL TRACT; IMAGE ANALYSIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; T LYMPHOCYTE; TIME LAPSE IMAGE ANALYSIS;

ANIMALS; ASTHMA; CELL COMMUNICATION; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; IMMUNOLOGIC FACTORS; INFLAMMATION; MICE; MICE, KNOCKOUT; PULMONARY EOSINOPHILIA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; T-LYMPHOCYTES; TH1 CELLS; URSODEOXYCHOLIC ACID;

EID: 84869494434     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12019     Document Type: Article

References (35)

1. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42: 1184-1193.
2. Combes B, Carithers RL Jr, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-1654.
3. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR,. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-2050.
4. Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005; 41: 896-905.
5. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N,. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134: 129-139.
6. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-364.
7. Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J, Inventors. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007; 56: 815-820.
8. Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007; 56: 1747-1753.
9. Yamazaki K, Gleich GJ, Kita H,. Bile acids induce eosinophil degranulation by two different mechanisms. Hepatology 2001; 33: 582-590.
10. Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999; 30: 71-78.
11. Wagner M, Zollner G, Trauner M,. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology 2008; 48: 1383-1386.
12. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W,. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48: 1632-1643.
13. Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001; 276: 47371-47378.
14. Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 2003; 278: 41930-41937.
15. van Rijt LS, Prins JB, Leenen PJ, Thielemans K, de Vries VC, Hoogsteden HC, et al. Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood 2002; 100: 3663-3671.
16. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA,. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000; 106: 551-559.
17. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006; 116: 2935-2944.
18. Kuipers H, Heirman C, Hijdra D, Muskens F, Willart M, van Meirvenne S, et al. Dendritic cells retrovirally overexpressing IL-12 induce strong Th1 responses to inhaled antigen in the lung but fail to revert established Th2 sensitization. J Leukoc Biol 2004; 76: 1028-1038.
19. Kuipers H, Hijdra D, De Vries VC, Hammad H, Prins JB, Coyle AJ, et al. Lipopolysaccharide-induced suppression of airway Th2 responses does not require IL-12 production by dendritic cells. J Immunol 2003; 171: 3645-3654.
20. Hammad H, Lambrecht BN,. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008; 8: 193-204.
21. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869-882.
22. van Rijt LS, Jung S, Kleinjan A, Vos N, Willart M, Duez C, et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005; 201: 981-991.
23. Hofmann AF, Hagey LR,. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008; 65: 2461-2483.
24. Wang H, Chen J, Hollister K, Sowers LC, Forman BM,. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-553.
25. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
26. Bulek K, Swaidani S, Aronica M, Li X,. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol 2010; 88 (): 257-268.
27. Klein Wolterink RG, KleinJan A, van Nimwegen M, Bergen I, de Bruijn M, Levan Y, et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012; 42: 1106-1116.
28. Garcia Z, Pradelli E, Celli S, Beuneu H, Simon A, Bousso P,. Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc Natl Acad Sci USA 2007; 104: 4553-4558.
29. Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA,. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 1998; 160: 4090-4097.
30. van Rijt LS, Vos N, Willart M, Kleinjan A, Coyle AJ, Hoogsteden HC, et al. Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma. J Allergy Clin Immunol 2004; 114: 166-173.
31. Denzler KL, Borchers MT, Crosby JR, Cieslewicz G, Hines EM, Justice JP, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol 2001; 167: 1672-1682.
32. Schote AB, Turner JD, Schiltz J, Muller CP,. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007; 44: 1436-1445.
33. Gueders MM, Paulissen G, Crahay C, Quesada-Calvo F, Hacha J, Van Hove C, et al. Mouse models of asthma: a comparison between C57BL/6 and BALB/c strains regarding bronchial responsiveness, inflammation, and cytokine production. Inflamm Res 2009; 58: 845-854.
34. Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, et al. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 2004; 164: 263-271.
35. Lawrence BP, Denison MS, Novak H, Vorderstrasse BA, Harrer N, Neruda W, et al. Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood 2008; 112: 1158-1165.